PDF-PREPARED REMARKS FTC Commissioner Phillips Taking Stock Assessing Co

Introduction Thank you for that introduction Scott I also want to thank Concurrences Review and NYU Stern for holding this excellent conference Im pleased to be here delivering my first public remarks. Inflation. Perfection. Deflation. 1. 2. But first a little behavioral economics. Setup and Operatio. n. Mike Zook . 20-Sep-2016. Hardware Overview. Driver Station. Start Up Order. Connect gamepads to USB hub. Plug hub into Driver Station Android. Open “FTC Driver Station” app. March 22, 2017. Presented by Ken Koss. Commissioner Committees. Finance & Administration:. President Picker (chair), and . Commissioner Guzman Aceves. Policy and Governance:. Commissioner Randolph (chair), and . STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. Commissioner Awards. William J. . Koller. District Commissioner. Seneca District. Commissioner Awards. What:. A number of awards . that are earned by . Commissioners who are . serving . units or working on District and Council Commissioner staffs.. Lucasz. . concept. Feedback on LHCb . cooling . review. B. . Verlaat, EP-DT-FS. 11 February 2016. Remarks:. On the current P&ID, there is no way to pressurize the detector from the . LUCASZ . plant to do a leak check for example. . TATEMENT OFOMMISSIONER OHIT HOPRARegardingthe Deception of Delivery Drivers by AmazoncomSee Laura Stevens Amazon Drives Deeper Into Package DeliveryALL TREET June 28 2018 https//wwwwsjcom/articles/am GEMINI 1 and GEMINI 2: Week 48 Data. DTG + 3TC . versus . DTG + TDF-FTC as Initial ART. GEMINI 1 and 2: Background. Source: Cahn P, et al. Lancet. 2019;393:143-55.. Study Design: GEMINI 1 and 2. Background. ROCKET II. Switching to TDF-FTC from ABC-3TC . for Hyperlipidemia . ROCKET II. : Study Design. Source: Behrens G, et al. . Antivir. . Ther. . . 2012;17:1011-20.. TDF-FTC + LPV-RTV. (. n = . 42). ABC-3TC + LPV-RTV. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg. iPrEx. Trial . Substudy. TDF-FTC versus Placebo as HIV . PrEP. for Transgender Women. iPrEx. . Substudy. : Study Design. Source: Deutsch MB, et al. Lancet HIV. 2015;2:e512-9.. Background. : . Subgroup analysis of the . SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed . RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID .